Comparison the efficacy of Attentalin and Atomoxetin in ADHD

Comparison of Attentalin and Atomoxetin in treatment of the attention deficit and hyper activity disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230419057960N1

Enrollment

Registered

2023-10-08

Start date

2023-11-11

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit and hyperactivity disorder. Attention-deficit hyperactivity disorders

Interventions

Intervention 1: Intervention group A: The patient s weight, blood pressure and pulse are measured, physical symptoms and complaints are asked from the patient and parents. In this group, patients are

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: Patients who recieved Attentin Deficite and Hyoeractivity Disorder due to DSM 5 criteria . Obtaining Informed consent from parents Age 6 to 12 years old

Exclusion criteria

Exclusion criteria: Seizures Glaucoma History of hyperthyroidism Eating disorders (anorexia) Children with a history of liver , kidney , heart diseases or other chronic illnesses requiring care Children who have taken MAOI medication for the 15 days prior to entering the study. substance abuse disorder

Design outcomes

Primary

Measure	Time frame
Symptoms of hyperactivity/attention deficit. Timepoint: before the trial and 3 and 6 weeks later. Method of measurement: ADHD Rating Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtiyeh Majidi

Hamedan University of Medical Sciences

meytalaat@gmail.com+98 81 3827 9345

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026